Figure 6. IL17A recruits CD103⁺ DC and potentiates CD8⁺ T-cell activation.

Bone marrow cells were treated with FLT3L (200 ng/ml) and GM-CSF (5 ng/ml) for 13 to 14 days to induce CD103⁺ DCs (iCD103 DCs). (A) Number of iCD103 DCs migrated to lower transwell chamber after 4 or 8 hours in response to increasing concentration of mouse rIL17A (0, 0.1, and 1ng/ml). (B) Number of iCD103 DCs migrated in transwell chamber after 3 hrs in response to 100 ul of lung homogenate freshly collected from Pts4^d/dIl17a^−/− mice at 7 months of age in the presence or absence of increasing dose of mouse rIL17A (0, 0.1, and 1ng/ml). (C) Representative histogram, and cumulative quantification of (D) IL17A receptor A (IL17RA), and (E) CD86 expression in iCD103 DCs treated with mouse rIL17A. (F) IFNγ concentration detected by ELISA after 72 hr coculture of splenic CD8⁺ T cells and iCD103 DCs or BMDCs treated with poly I:C (5 μg/ml) or IL17A at indicated concentration in the presence of anti-CD3 (1 μg/ml). (G) IFNγ concentration detected by ELISA after 72 hr coculture of splenic OT-1 CD8⁺ T cells and iCD103 DCs treated with poly I:C (5 μg/ml) or mouse rIL17A at indicated concentration with or without pretreatment of OVA. Data are mean ± SEM and representative of two independent experiments; *** P < 0.001, ** P < 0.01, * P < 0.05 as determined by the one-way ANOVA and Bonferroni’s Multiple Comparison test. Please also see Supplementary Figs. S10 and S11.